Plasma and tissue osteopontin in relation to plasma selenium in patients with psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 1, 2012, Pages 66-70

  Kadry, D ^a   Rashed, L ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; SELENIUM;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; TISSUE LEVEL; WAIST CIRCUMFERENCE;

ADULT; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPONTIN; PSORIASIS; SELENIUM;

EID: 83755186053     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04010.x     Document Type: Article

References (26)

1. Neimann AL, Porter SB, Gelfand JM,. Epidemiology of psoriasis. Expert Rev Dermatol 2006; 1: 63-75.
2. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835. (Pubitemid 44556851)
3. Wilson PW, D'Agostino RB, Parise H, et al. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072. (Pubitemid 43113437)
4. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-864. (Pubitemid 30084330)
5. Renkl AC, Wussler J, Ahrens T, et al. Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 2005; 106: 946-955. (Pubitemid 41076439)
6. Giachelli CM, Liaw L, Murry CE, et al. Osteopontin expression in cardiovascular diseases. Ann N Y Acad Sci 1995; 760: 109-126.
7. Minoretti P, Falcone C, Calcagnino M, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006; 27: 802-807.
8. Burk RF,. Selenium, an antioxidant nutrient. Nutr Clin Care 2002; 5: 75-79.
9. Rayman MP,. The importance of selenium to human health. Lancet 2000; 356: 233-241. (Pubitemid 30446984)
10. Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, Guallar E,. Selenium and coronary heart disease: a meta-analysis. Am J Clin Nutr 2006; 84: 762-773. (Pubitemid 44715658)
11. Unni E, Kittrell FS, Singh U, Sinha R,. Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine. Breast Cancer Res 2004; 6: R586-R592.
12. Fredriksson T, Petersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. (Pubitemid 8387357)
13. Alberti KG, Zimmet P, Shaw J,. Metabolic syndrome-a new world-wide definition. A Consensus statement from the international Diabetes Federation. Diabet Med 2006; 23: 469-480. Review.
14. Carr DB, Utzschneider KM, Hull RL, et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult treatment Panel III criteria for the metabolic syndrome. Diabetes 2004; 53: 2087-2094. (Pubitemid 38970759)
15. Chen Y-J, Shen J-L, Wu C-Y, et al. Elevated plasma osteopontin level is associated with occurrence of psoriasis and is an unfavorable cardiovascular risk factor in patients with psoriasis. J Am Acad Dermatol 2009; 60 (Suppl. 2): 225-230.
16. Buommino E, Tufano MA, Balato N, et al. Osteopontin: a new emerging role in psoriasis. Arch Dermatol Res 2009; 301: 397-404.
17. Clark RA, Kupper TS,. Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest 2006; 116: 2084-2087. (Pubitemid 44162315)
18. Serwin AB, Wasowicz W, Gromadzinska J, Chodynicka B,. Selenium status in psoriasis and its relations to the duration and severity of the disease. Nutrition 2003; 19: 301-304. (Pubitemid 36390121)
19. Kharaeva Z, Gostova E, Der Luca C, et al. Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients. Nutrition 2009; 25: 295-302.
20. Maggini S, Wintergerst ES, Beveridge S, Hornig DH,. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br J Nutr 2007; 98: S29-S35. (Pubitemid 47558856)
21. Matsushima K, Oppenheim JJ,. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL-1 and TNF. Cytokines 1989; 1: 2-13.
22. Larsen CG, Anderson AO, Apella E, et al. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243: 1464-1466. (Pubitemid 19087128)
23. Tuschil A, Lam C, Halsberger A, Lindley I,. Interleukin-8 stimulates calcium transients and promotes epidermal cell proliferation. J Invest Dermatol 1992; 99: 294-298.
24. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798-1801. (Pubitemid 23087348)
25. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006; 21: 1-6. (Pubitemid 43194325)
26. Wysocki J, Skoczynski S, Strozik A, et al. [Metabolic or immunometabolic syndrome?] Wiad Lek 2005; 58: 124-127.